Foster City, California, United States, November 9, 2026
OrthoTrophix, Inc. has announced new clinical research findings from two scientific poster presentations at ACR Convergence 2026, highlighting the potential of its investigational therapy TPX-100 in patients with knee osteoarthritis (KOA). The presentations, held during the American College of Rheumatology annual meeting in Orlando, Florida, examine the relationship between meniscal damage, femoral bone-shape changes and clinical treatment responses. The findings provide additional insights into the structural progression of knee osteoarthritis and identify patient characteristics that may help predict treatment response. TPX-100 is being developed as a potential disease-modifying osteoarthritis drug (DMOAD) designed to protect joint structures and potentially slow disease progression. According to the company, the new analyses suggest that patients with more severe meniscal pathology may experience greater and more sustained functional improvements following TPX-100 treatment compared with placebo. The findings also indicate that treatment may influence the relationship between meniscal degeneration and changes in the underlying bone structure. These results represent an important development in the investigation of disease-modifying approaches for knee osteoarthritis, a condition affecting millions of people worldwide.
TPX-100 Research Reveals Relationship Between Bone Shape and Meniscal Damage
The first scientific poster, numbered 1581 and presented on November 9, reported findings from a retrospective magnetic resonance imaging (MRI) analysis of a one-year, double-blind Phase 2a clinical study evaluating intra-articular TPX-100. Researchers investigated the association between femoral bone shape and meniscal pathology using an imaging measurement known as the B-score. The analysis demonstrated a significant relationship between baseline meniscal pathology and femoral bone-shape measurements at six and twelve months. The meniscus is an important structure within the knee joint that distributes mechanical loads, absorbs impact and contributes to joint stability. Meniscal degeneration, including tears and displacement, can disrupt normal joint mechanics and contribute to osteoarthritis progression. In placebo-treated knees, the association between bone-shape changes and meniscal pathology became stronger over time. In contrast, TPX-100-treated knees demonstrated stabilization of bone shape and a weakening of this relationship. These observations suggest that the investigational therapy may influence structural changes associated with knee osteoarthritis, particularly in patients with substantial meniscal disease. However, the findings are based on retrospective imaging analyses and require further prospective clinical validation.
Greater Meniscal Damage Associated With Better Treatment Response
The second poster, numbered 2568 and scheduled for presentation on November 10, examined whether baseline meniscal pathology could help identify patients most likely to benefit from TPX-100 treatment. The analysis found that patients with more severe meniscal damage at the beginning of the study experienced greater and more durable improvements in patient-reported outcomes with TPX-100 compared with placebo. The strongest improvements were observed in knee function, assessed using a validated measurement covering 17 everyday activities. These activities included walking, climbing stairs, standing up from a chair and performing other routine movements that can become difficult for individuals with knee osteoarthritis. The findings suggest that the severity of meniscal pathology may influence how patients respond to treatment. Identifying such characteristics could eventually help researchers select appropriate patient populations for future clinical trials. The company believes these findings may support the development of more targeted treatment strategies for individuals with structural joint damage. Importantly, the observed relationship between meniscal disease severity and treatment response remains exploratory and will need confirmation in larger prospective studies before it can be used as a reliable patient-selection approach.
Advertisement
Clinical Development and Future Potential of TPX-100
TPX-100 is OrthoTrophix’s lead investigational therapeutic candidate and is being developed to address the underlying structural changes associated with osteoarthritis. Unlike conventional treatments that primarily focus on reducing pain and inflammation, the company’s research strategy aims to preserve joint integrity and potentially modify disease progression. The therapy is administered through intra-articular injection, delivering the investigational treatment directly into the affected joint. Its development focuses on subchondral bone and cartilage-related structural changes, which are increasingly recognized as important contributors to osteoarthritis progression. OrthoTrophix is advancing TPX-100 through a broader clinical development program, including a Phase 2b trial evaluating its safety and efficacy in patients with mild to severe tibiofemoral knee osteoarthritis. The company announced in February 2026 that it had completed enrollment ahead of schedule in this study, which is designed to further investigate findings from earlier clinical research. OrthoTrophix has also partnered with American Regent for U.S. development and commercialization of TPX-100. The latest ACR 2026 findings strengthen the scientific rationale for continued investigation of TPX-100 and provide additional information about potential structural biomarkers and patient characteristics associated with treatment response. The two presentations represent an important research milestone for OrthoTrophix and its osteoarthritis development program. By connecting meniscal pathology, bone remodeling and functional outcomes, the findings provide a deeper understanding of knee osteoarthritis progression. Further clinical studies will determine whether TPX-100 can deliver meaningful and sustained disease-modifying benefits and establish its potential role in future osteoarthritis treatment strategies.
Source: OrthoTrophix press release
